| The bioavailability of orally administered des-aspartate-angiotensin I (DAA-I) was investigated in human subjects. |
| Prostaglandin E2 metabolite (PGEM), a stable metabolite derivative of PGE2 was measured as a biomarker of DAA-I in plasma samples obtained from 15 subjects in a single-dose phase I trial on DAA-I. |
| Plasma of two of the three subjects who were administered a preclinical efficacious dose of DAA-I (0.7 mg/kg) showed a significant PGEM peak concentration at 5–6 h postdose. No similar significant PGEM peak was present in the plasma of the other subjects who were administered a subefficacious and a two-time efficacious dose. This observation was in concordance with the known in vivo actions of DAA-I. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.